Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer

Acta Oncologica

Volumn 47, Issue 1, 2008, Pages 38-46

  Sutela, Anna ^a   Vanninen, Ritva ^a   Sudah, Mazen ^a   Berg, Marja ^a   Kiviniemi, Vesa ^b   Rummukainen, Jaana ^a   Kataja, Vesa ^a   Kärjä, Vesa ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BREAST CANCER; CELL HETEROGENEITY; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STEREOTACTIC BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 37549004060     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701441822     Document Type: Article

References (21)

1. Parker SH, Lovin JD, Jobe WE, Luethke JM, Hopper KD, Yakes WF, et al. Stereotactic breast biopsy with a biopsy gun. Radiology 1990;176:741-7.
2. Verkooijen HM, Peeters PH, Buskens E, Koot VC, Borel Rinkes IH, Mali WP, et al. Diagnostic accuracy of large-core needle biopsy for nonpalpable breast disease: A meta-analysis. Br J Cancer 2000;82:1017-21.
3. Denley H, Pinder SE, Elston CW, Lee AH, Ellis IO. Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol 2001;54:20-4.
4. Douglas-Jones AG, Collett N, Morgan JM, Jasani B. Comparison of core oestrogen receptor (ER) assay with excised tumour: Intratumoral distribution of ER in breast carcinoma. J Clin Pathol 2001;54:951-5.
5. Mueller-Holzner E, Fink V, Frede T, Marth C. Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: A reliable predictor of HER2 status of the whole tumor. Breast Cancer Res Treat 2001;69:13-9.
6. Lake DE, Hudis C. Aromatase inhibitors in breast cancer: An update. Cancer Control 2002;9:490-8.
7. Coleman RE. Current and future status of adjuvant therapy for breast cancer. Cancer 2003;97:880-6.
8. Bhargava R, Lal P, Chen B. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: Does it measure up to fluorescence in situ hybridization? Am J Clin Pathol 2005;123:237-43.
9. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
11. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
12. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.
13. Zidan A, Christie Brown JS, Peston D, Shousha S. Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma. J Clin Pathol 1997;50:27-9.
14. Connor CS, Tawfik OW, Joyce AJ, Davis MK, Mayo MS, Jewell WR. A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens. Am J Surg 2002;184:322-4.
15. Badoual C, Maruani A, Ghorra C, Lebas P, Avigdor S, Michenet P. Pathological prognostic factors of invasive breast carcinoma in ultrasound-guided large core biopsies-correlation with subsequent surgical excisions. Breast 2005;14:22-7.
16. Mann GB, Fahey VD, Feleppa F, Buchanan MR. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 2005;23:5148-54.
17. Becker L, Taves D, McCurdy L, Muscedere G, Karlik S, Ward S. Stereotactic core biopsy of breast microcalcifications: Comparison of film versus digital mammography, both using an add-on unit. AJR Am J Roentgenol 2001;177:1451-7.
18. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
19. Bankfalvi A, Simon R, Brandt B, Burger H, Vollmer I, Dockhorn-Dworniczak B, et al. Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology 2000;37:411-9.
20. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, et al. Current perspectives on HER2 testing: A review of national testing guidelines. Mod Pathol 2003;16:173-82.
21. Liberman L, Dershaw DD, Rosen PP, Abramson AF, Deutch BM, Hann LE. Stereotaxic 14-gauge breast biopsy: How many core biopsy specimens are needed? Radiology 1994;192:793-5